ACID Acer Inc (GDR)

Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital

Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital
EN
01/10/2020

Underlying

ACIDAcer Inc (GDR)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Acer Inc (GDR)

 PRESS RELEASE
Free
ACID ACER INC (GDR)

Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital

Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital

October 1, 2020 1 EN
 PRESS RELEASE
Free
ACID ACER INC (GDR)

Acer Therapeutics to Virtually Present at Upcoming Investor Conference...

Acer Therapeutics to Virtually Present at Upcoming Investor Conferences NEWTON, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a virtual corporate overview at upcoming investor conferences in September, including the LD Micro 500 Virtual Conference and the H.C. Wainwright 22nd Annual Global Investment Conference. Acer...

August 25, 2020 1 EN
 PRESS RELEASE
Free
ACID ACER INC (GDR)

Acer Therapeutics Reports Second Quarter 2020 Financial Results and Pr...

Acer Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update Advanced expanded pipeline of clinical stage product candidates, including emetine for COVID-19 and ACER-001 for Urea Cycle Disorders NEWTON, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2020, and pr...

August 13, 2020 1 EN
 PRESS RELEASE
Free
ACID ACER INC (GDR)

Acer Therapeutics Announces Administration of ACER-001 in a Fasted Sta...

Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study Model suggests ACER-001, Acer’s taste-masked, immediate release formulation of sodium phenylbutyrate, may offer improved disease management in patients with Urea Cycle Disorders compared to current treatments Anticipate submitting ACER-001 NDA in H1 2021 assuming successful completion of additional nonclinical work and long-term stability data, and subject to additional capital NEWTON, Mass., July 08, 2020 (GLOBE NEWSWIRE) -- Acer ...

July 8, 2020 1 EN
 PRESS RELEASE
Free
ACID ACER INC (GDR)

Acer Therapeutics Reports First Quarter 2020 Financial Results and Pro...

Acer Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update Expanded pipeline with addition of emetine for COVID-19; progressed ACER-001, osanetant and EDSIVO™ programs; and entered into stock purchase agreement with Lincoln Park Capital NEWTON, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the first qua...

May 14, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch